Loading…
Spyre Therapeutics, Inc. is projected to rise to $142.37 by 2027, a +40% move from its current price of $101.50. SYRE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $98.18 | $101.54 | $105.03 | +0.04% |
| Aug 2 | $96.86 | $101.59 | $106.56 | +0.09% |
| Aug 3 | $95.86 | $101.63 | $107.75 | +0.13% |
| Aug 4 | $95.04 | $101.68 | $108.78 | +0.18% |
| Aug 5 | $94.33 | $101.72 | $109.70 | +0.22% |
| Aug 6 | $93.70 | $101.77 | $110.54 | +0.27% |
| Aug 7 | $93.12 | $101.81 | $111.32 | +0.31% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $93.12 | $101.81 | $111.32 | +0.31% |
| Week 2 | $90.01 | $102.13 | $115.88 | +0.62% |
| Week 3 | $87.77 | $102.45 | $119.58 | +0.93% |
| Week 4 | $85.96 | $102.76 | $122.86 | +1.25% |
| Week 5 | $84.43 | $103.08 | $125.86 | +1.56% |
| Week 6 | $83.09 | $103.40 | $128.68 | +1.87% |
| Week 7 | $81.90 | $103.72 | $131.36 | +2.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Spyre Therapeutics, Inc. is a clinical stage biotechnology company focused on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc.
in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Spyre Therapeutics, Inc. (SYRE) is listed with a current price of $102.70 and a market capitalization of $8.92B, ranking 972 in its market. The stock operates within the Healthcare sector, focusing on inflammatory diseases and immunology therapeutics.
The current price sits within a broader forecasted trajectory that envisions substantial upside over the coming years, with the avg forecast price rising from $102.70 in 2026 to $1,644.49 by 2050.
Key near-term metrics show RSI of 60, a 50-day simple moving average of $83.48 and a 200-day simple moving average of $49.10. The stock has a defined support level at $72.00 and a resistance at $102.70, with a 30-day range of $79.29 to $133.02. Annualized volatility is estimated at 70%.
A major floor 58.4% below — a decisive break under it would weaken the trend.
The nearest floor, 15.0% below — buyers have tended to step in here.
Price is pressing into resistance (1.2% away) — a breakout level to watch.
A major ceiling 11.6% above — clearing it would confirm fresh momentum.
Key SYRE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SYRE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $100.30 | Buy | $100.11 | Buy |
| MA 10 | $100.09 | Buy | $99.48 | Buy |
| MA 20 | $97.56 | Buy | $97.07 | Buy |
| MA 50 | $87.02 | Buy | $88.34 | Buy |
| MA 100 | $73.05 | Buy | $75.70 | Buy |
| MA 200 | $51.99 | Buy | $59.39 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.22 | Neutral |
| Stoch RSI (14) | 32.43 | Neutral |
| CCI (20) | 80.08 | Neutral |
| Williams %R (14) | -13.38 | Info |
| MACD (12,26,9) | -0.53 | Sell |
| ROC (12) | 2.58 | Buy |
| Bollinger %B (20,2) | 0.73 | Neutral |
| Stochastic %K (14) | 86.62 | Sell |
| TRIX (15) | 0.70 | Buy |
| Awesome (5,34) | 6.66 | Buy |
| Ultimate (7,14,28) | 49.67 | Neutral |
| Momentum (10) | 7.38 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 99.61 | Buy |
| ADX (14) | 19.30 | Neutral |
| ATR (14) | 3.02 | Info |
The 30-day technical picture presents a bullish tone overall. The sentiment is bullish, supported by a current price near the established resistance at $102.70 and above the SMA50 of $83.48, while the SMA200 sits at $49.10.
Traders may note the 30-day range spans from $79.29 to $133.02, with a defined $72.00 support level. The RSI14 at 60 also aligns with a constructive but not overbought backdrop, suggesting room for continued movement within the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $29.96 | $101.50 | $144.85 | 0% | Neutral | |
| $111.09 | $142.37 | $194.33 | +40% | Bullish | |
| $142.60 | $189.41 | $270.42 | +87% | Bullish | |
| $164.35 | $224.88 | $332.41 | +122% | Bullish | |
| $192.99 | $271.14 | $412.58 | +167% | Bullish | |
| $201.38 | $289.84 | $452.27 | +186% | Bullish | |
| $198.55 | $292.29 | $466.46 | +188% | Bullish | |
| $235.67 | $354.39 | $577.14 | +249% | Bullish | |
| $280.24 | $430.06 | $713.51 | +324% | Bullish | |
| $333.66 | $522.13 | $881.29 | +414% | Bullish | |
| $424.96 | $727.37 | $1,318.86 | +617% | Bullish | |
| $838.55 | $1,683.35 | $3,383.46 | +15.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $29.96 | $101.50 | $118.41 | +0.00% |
| August 2026 | $85.22 | $100.51 | $121.69 | -0.97% |
| September 2026 | $88.67 | $105.68 | $130.06 | +5.14% |
| October 2026 | $90.12 | $108.30 | $135.02 | +2.49% |
| November 2026 | $89.42 | $108.20 | $136.30 | -0.09% |
| December 2026 | $93.54 | $113.91 | $144.85 | +5.28% |
Click any year to see its month-by-month SYRE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SYRE price prediction for 2026 points to an average of $101.50 (low $29.96, high $144.85) — a potential gain of 0% on today's $101.50. Price action looks broadly range-bound.
In 2027, SYRE is projected to trade between $111.09 and $194.33, averaging $142.37 — a potential gain of +40% from today's $101.50. That is up +40% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Spyre Therapeutics, Inc.'s 2028 outlook centres on $189.41, within a $142.60 to $270.42 range. That is up +33% on the projected 2027 average. That marks a +87% change versus current levels. Momentum favours further upside here.
By 2029, SYRE could reach as high as $332.41, with a base case around $224.88 and support toward $164.35 — roughly +122% from $101.50. Buyers look set to stay in control over this stretch.
Expect SYRE to range from $192.99 to $412.58 through 2030. The $271.14 average target implies a +167% move from current prices. That is up +21% on the projected 2029 average. Momentum favours further upside here.
The SYRE price prediction for 2031 points to an average of $289.84 (low $201.38, high $452.27) — a potential gain of +186% on today's $101.50. Buyers look set to stay in control over this stretch.
In 2032, SYRE is projected to trade between $198.55 and $466.46, averaging $292.29 — a potential gain of +188% from today's $101.50. That is up +1% on the projected 2031 average. Momentum favours further upside here.
Spyre Therapeutics, Inc.'s 2033 outlook centres on $354.39, within a $235.67 to $577.14 range. That is up +21% on the projected 2032 average. That marks a +249% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, SYRE could reach as high as $713.51, with a base case around $430.06 and support toward $280.24 — roughly +324% from $101.50. Momentum favours further upside here.
Expect SYRE to range from $333.66 to $881.29 through 2035. The $522.13 average target implies a +414% move from current prices. That is up +21% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The SYRE price prediction for 2040 points to an average of $727.37 (low $424.96, high $1,318.86) — a potential gain of +617% on today's $101.50. Momentum favours further upside here.
In 2050, SYRE is projected to trade between $838.55 and $3,383.46, averaging $1,683.35 — a potential gain of +15.6x from today's $101.50. That is up +131% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in SYRE today (≈ 9.852217 SYRE) could be worth
$16,584.76
+$15,584.76 (+1558%) by 2050 · US Dollar
Based on the average projected SYRE price of $1,683.35 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SYREwould be worth at today's price.
$1,000 invested in SYRE on Jul 30, 2025 (≈ 57.836897 SYRE) would be worth
$5,870.45
+$4,870.45 (+487.0%) today · 5.87× · US Dollar
Based on a SYRE entry price of $17.29 vs. today's $101.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $99.99 | $1,015.1 | +1.5% |
| 1 month ago | $88.78 | $1,143.28 | +14.3% |
| 3 months ago | $69.42 | $1,462.11 | +46.2% |
| 6 months ago | $31.98 | $3,173.86 | +217.4% |
| 1 year ago | $17.29 | $5,870.45 | +487.0% |
| All time (5.0y) ago | $153.75 | $660.16 | -34.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SYRE forecast.
Our base-case forecast reaches $200.00 around 2029.
Implied market cap at $200.00: $17.37B
The multi-year forecast shows a clear upward trajectory across the period, with 2026 averaging $102.70 and 2027-2050 highlighting bullish momentum. By 2030 the average price is forecast at $274.61 with a 167.4% ROI, and the 2035 forecast projects an average of $525.99 with a 412.2% ROI. The path continues higher, with 2040 averaging $697.98 (579.6% ROI) and 2050 averaging $1,644.49 (1501.3% ROI).
Sentiment remains bullish across most years, culminating in a 2050 bullish outlook at an average of $1,644.49.
These figures illustrate a long-run upside, but they are estimates and not guarantees. Investors should consider the potential for volatility and downside risk alongside the projected upside.
Tap a question to reveal the answer.
Min: $29.96, Avg: $102.70, Max: $153.14; ROI: 0%; Sentiment: NEUTRAL.
Current price is $102.70 and market capitalization is $8.92B.
Min: $188.24, Avg: $274.61, Max: $434.34; ROI: 167.4%; Sentiment: BULLISH.
Yes. Forecasts from 2027 onward show BULLISH sentiment, with 2040 at an avg of $697.98 and 2050 at an avg of $1,644.49 (ROI 579.6% and 1501.3%, respectively).
2035 forecast shows Min: $316.17, Avg: $525.99, Max: $933.45 with ROI: 412.2% and sentiment BULLISH, indicating upside beyond $400 is projected in that year.
Spyre Therapeutics, Inc. Community Discussion
0Share your Spyre Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.